Europe Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)
The Europe Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 12,324.2 million by 2031, up from US$ 1,437.8 million in 2024, with an estimated compound annual growth rate (CAGR) of 37.4% from 2025 to 2031.
Executive Summary and Market Analysis
The anti-obesity drugs market in Europe is divided into several key regions: Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market is witnessing robust growth driven by increasing obesity rates and supportive government policies. Factors such as sedentary lifestyles, poor dietary habits, and an aging population are contributing to the rising prevalence of obesity, which in turn is fueling the demand for effective medical treatments. The association of obesity with chronic diseases like type 2 diabetes, cardiovascular diseases, and certain cancers has intensified the need for effective interventions. Advances in technology and the emergence of safer and more effective weight-loss medications, particularly GLP-1 receptor agonists, are also propelling market growth. Regulatory approvals and favorable reimbursement policies in countries such as Germany, France, and the UK enhance access to these treatments. Furthermore, increased investments from pharmaceutical companies and strategic partnerships within the healthcare sector are fostering innovation and expanding product availability. Public awareness campaigns and a shift in perceptions regarding obesity as a treatable medical condition are encouraging more individuals to seek pharmacological assistance for weight management.
Strategic Insights
Market Segmentation Analysis
The increasing awareness of obesity and its associated health risks has significantly boosted the demand for effective weight management solutions. Concerns regarding lifestyle-related diseases have prompted many individuals to seek medical and pharmaceutical assistance. This growing awareness is leading to greater acceptance and utilization of anti-obesity drugs in treatment regimens. Public health campaigns and media coverage are informing the public about available options for managing obesity, resulting in rapid market growth. The recognition of obesity as a chronic condition in Europe has further spurred interest in medical weight-loss treatments. A study published in April 2025 indicated that GLP-1 drugs are increasingly prescribed off-label for obesity, particularly among women and native Swedes, highlighting a shift towards newer treatment options. This trend reflects a broader change in consumer behavior and healthcare strategies towards managing obesity with scientific and pharmaceutical support, positioning the anti-obesity drugs market for sustained growth driven by ongoing advancements and rising patient demand.
Country Insights
The market is analyzed by country, focusing on Germany, the UK, France, Spain, Italy, and the Rest of Europe, with Germany holding the largest market share in 2024. Germany faces a significant public health challenge due to a high percentage of its adult population being classified as overweight or obese. Reports indicate that nearly half of German adults are slightly overweight, and about one in five are obese, creating a substantial market opportunity for anti-obesity drugs. The economic burden associated with obesity-related healthcare costs and productivity losses underscores the need for effective interventions, with studies showing that the costs of new weight-loss drugs are outweighed by the savings from reduced healthcare expenses.
Company Profiles
Key players in the Europe Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
Executive Summary and Market Analysis
The anti-obesity drugs market in Europe is divided into several key regions: Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market is witnessing robust growth driven by increasing obesity rates and supportive government policies. Factors such as sedentary lifestyles, poor dietary habits, and an aging population are contributing to the rising prevalence of obesity, which in turn is fueling the demand for effective medical treatments. The association of obesity with chronic diseases like type 2 diabetes, cardiovascular diseases, and certain cancers has intensified the need for effective interventions. Advances in technology and the emergence of safer and more effective weight-loss medications, particularly GLP-1 receptor agonists, are also propelling market growth. Regulatory approvals and favorable reimbursement policies in countries such as Germany, France, and the UK enhance access to these treatments. Furthermore, increased investments from pharmaceutical companies and strategic partnerships within the healthcare sector are fostering innovation and expanding product availability. Public awareness campaigns and a shift in perceptions regarding obesity as a treatable medical condition are encouraging more individuals to seek pharmacological assistance for weight management.
Strategic Insights
Market Segmentation Analysis
- By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.
- By Mechanism of Action: The market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.
- By Drug Class: The market includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, with GLP-1 Agonists dominating the market in 2024.
- By GLP-1 Agonist: This segment includes Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide having the largest share in 2024.
- By Application: The market is divided into Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading in market share in 2024.
- By Route of Administration: The market is segmented into Oral and Parenteral, with Oral administration holding the largest share in 2024.
- By Distribution Channel: The market includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies leading in market share in 2024.
The increasing awareness of obesity and its associated health risks has significantly boosted the demand for effective weight management solutions. Concerns regarding lifestyle-related diseases have prompted many individuals to seek medical and pharmaceutical assistance. This growing awareness is leading to greater acceptance and utilization of anti-obesity drugs in treatment regimens. Public health campaigns and media coverage are informing the public about available options for managing obesity, resulting in rapid market growth. The recognition of obesity as a chronic condition in Europe has further spurred interest in medical weight-loss treatments. A study published in April 2025 indicated that GLP-1 drugs are increasingly prescribed off-label for obesity, particularly among women and native Swedes, highlighting a shift towards newer treatment options. This trend reflects a broader change in consumer behavior and healthcare strategies towards managing obesity with scientific and pharmaceutical support, positioning the anti-obesity drugs market for sustained growth driven by ongoing advancements and rising patient demand.
Country Insights
The market is analyzed by country, focusing on Germany, the UK, France, Spain, Italy, and the Rest of Europe, with Germany holding the largest market share in 2024. Germany faces a significant public health challenge due to a high percentage of its adult population being classified as overweight or obese. Reports indicate that nearly half of German adults are slightly overweight, and about one in five are obese, creating a substantial market opportunity for anti-obesity drugs. The economic burden associated with obesity-related healthcare costs and productivity losses underscores the need for effective interventions, with studies showing that the costs of new weight-loss drugs are outweighed by the savings from reduced healthcare expenses.
Company Profiles
Key players in the Europe Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. EUROPE ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Europe Anti-Obesity Drugs Market Forecast and Analysis
7. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. EUROPE ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Europe
14.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Germany: Europe Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Germany: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Germany: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Germany: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.1.2.2.5 Germany: Europe Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Germany: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Germany: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.2.3.3.5 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 France: Europe Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 France: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 France: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 France: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.3.4.4.5 France: Europe Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 France: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 France: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Spain: Europe Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Spain: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Spain: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Spain: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.4.5.5.5 Spain: Europe Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Spain: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Spain: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.5.6.6 Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.5.6.6.1 Italy: Europe Anti-Obesity Drugs Market Share - by Type
14.5.6.6.2 Italy: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.5.6.6.3 Italy: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.5.6.6.4 Italy: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.5.6.6.5 Italy: Europe Anti-Obesity Drugs Market Share - by Application
14.5.6.6.6 Italy: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.5.6.6.7 Italy: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.6.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.6.7.7.1 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Type
14.6.7.7.2 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.6.7.7.3 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.6.7.7.4 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.6.7.7.5 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Application
14.6.7.7.6 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.6.7.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. EUROPE ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - EUROPE MARKET ANALYSIS
6.1 Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Europe Anti-Obesity Drugs Market Forecast and Analysis
7. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. EUROPE ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. EUROPE ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Europe
14.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Germany: Europe Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Germany: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Germany: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Germany: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.1.2.2.5 Germany: Europe Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Germany: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Germany: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.2.3.3.5 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 France: Europe Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 France: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 France: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 France: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.3.4.4.5 France: Europe Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 France: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 France: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Spain: Europe Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Spain: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Spain: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Spain: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.4.5.5.5 Spain: Europe Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Spain: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Spain: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.5.6.6 Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.5.6.6.1 Italy: Europe Anti-Obesity Drugs Market Share - by Type
14.5.6.6.2 Italy: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.5.6.6.3 Italy: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.5.6.6.4 Italy: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.5.6.6.5 Italy: Europe Anti-Obesity Drugs Market Share - by Application
14.5.6.6.6 Italy: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.5.6.6.7 Italy: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.6.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.6.7.7.1 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Type
14.6.7.7.2 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.6.7.7.3 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.6.7.7.4 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.6.7.7.5 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Application
14.6.7.7.6 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.6.7.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
LIST OF TABLES
Table 1. Europe Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 8. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 16. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 23. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 30. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 37. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 41. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 42. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 43. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 44. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 45. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 46. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 47. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 48. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 49. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 50. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 51. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 52. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 53. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 54. Heat Map Analysis by Key Players
Table 1. Europe Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 8. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 16. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 23. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 30. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 37. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 41. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 42. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 43. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 44. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 45. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 46. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 47. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 48. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 49. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 50. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 51. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 52. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 53. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 54. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Europe Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Europe Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Europe Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Europe Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Europe Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Europe Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Europe Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Europe Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Europe Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Europe Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 41. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 42. Company Positioning & Concentration
Figure 1. Europe Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Europe Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Europe Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Europe Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Europe Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Europe Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Europe Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Europe Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Europe Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Europe Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 41. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 42. Company Positioning & Concentration
